Fournier Gangrene Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Pharmacovigilance Study with Data from the U.S. FDA Adverse Event Reporting System

Background. The U.S. Food and Drug Administration (FDA) released a safety warning of Fournier gangrene (FG), a rare but serious adverse effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors in August 2018. However, existing studies have focused mainly on individual FG case reports. Although se...

Full description

Saved in:
Bibliographic Details
Main Authors: Yang Hu, Ziyu Bai, Yan Tang, Rongji Liu, Bin Zhao, Jian Gong, Dan Mei
Format: Article
Language:English
Published: Wiley 2020-01-01
Series:Journal of Diabetes Research
Online Access:http://dx.doi.org/10.1155/2020/3695101
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832566124986761216
author Yang Hu
Ziyu Bai
Yan Tang
Rongji Liu
Bin Zhao
Jian Gong
Dan Mei
author_facet Yang Hu
Ziyu Bai
Yan Tang
Rongji Liu
Bin Zhao
Jian Gong
Dan Mei
author_sort Yang Hu
collection DOAJ
description Background. The U.S. Food and Drug Administration (FDA) released a safety warning of Fournier gangrene (FG), a rare but serious adverse effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors in August 2018. However, existing studies have focused mainly on individual FG case reports. Although several previous studies conducted reviews of cases, objective scientific analysis was not applied, and the prognosis data were inadequate. Objective. This study is aimed at presenting data supplementary to existing studies by analysing postmarketing adverse event reports in the FDA Adverse Events Reporting System (FAERS) database. Multiple statistical analysis methods were applied to evaluate the potential association between SGLT2 inhibitors and FG, thus providing reliable and professionalized medication usage recommendations for SGLT2 inhibitors in clinical practice. Methods. Disproportionality analysis and Bayesian analysis were applied for data mining among the suspected adverse event reports of FG associated with SGLT2 inhibitors recorded in the FAERS database during the period from January 2004 to September 2019. Results. There were 542 FG cases identified in the FAERS database in patients receiving SGLT2 inhibitors. Among all SGLT2 inhibitor therapies, empagliflozin was associated with the highest number of FG reports (232 in total), while empagliflozin plus metformin had the strongest association with FG occurrence with the reporting odds ratio (ROR 54.79, 95% two-sided CI 31.56 to 95.12) and proportional reporting ratio (PRR 53.36, χ2 666.70). There were 391 patients who underwent initial or prolonged hospitalization (72.14%), and 26 patients died (4.81%). Three new FG cases caused by ertugliflozin were found in 2019. Conclusion. The analysis of SGLT2 inhibitor-associated FG reports in the FAERS database identified signals between the drug and adverse events of interest. It also provides comprehensive information on the characteristics of FG onset and prognosis. Clinicians should pay more attention to this rare but severe adverse event when prescribing SGLT2 inhibitors in clinical practice.
format Article
id doaj-art-4e9903a0dc0849c1a79f1b19342b6220
institution Kabale University
issn 2314-6745
2314-6753
language English
publishDate 2020-01-01
publisher Wiley
record_format Article
series Journal of Diabetes Research
spelling doaj-art-4e9903a0dc0849c1a79f1b19342b62202025-02-03T01:05:04ZengWileyJournal of Diabetes Research2314-67452314-67532020-01-01202010.1155/2020/36951013695101Fournier Gangrene Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Pharmacovigilance Study with Data from the U.S. FDA Adverse Event Reporting SystemYang Hu0Ziyu Bai1Yan Tang2Rongji Liu3Bin Zhao4Jian Gong5Dan Mei6Pharmacy Department, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, ChinaSchool of Pharmacy, Tianjin University of Traditional Chinese Medicine, Tianjin, ChinaPharmacy Department, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, ChinaPharmacy Department, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, ChinaPharmacy Department, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, ChinaResearch Group of Pharmacoepidemiology and Clinical Drug Evaluation, Shenyang Pharmaceutical University, Liaoning, ChinaPharmacy Department, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, ChinaBackground. The U.S. Food and Drug Administration (FDA) released a safety warning of Fournier gangrene (FG), a rare but serious adverse effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors in August 2018. However, existing studies have focused mainly on individual FG case reports. Although several previous studies conducted reviews of cases, objective scientific analysis was not applied, and the prognosis data were inadequate. Objective. This study is aimed at presenting data supplementary to existing studies by analysing postmarketing adverse event reports in the FDA Adverse Events Reporting System (FAERS) database. Multiple statistical analysis methods were applied to evaluate the potential association between SGLT2 inhibitors and FG, thus providing reliable and professionalized medication usage recommendations for SGLT2 inhibitors in clinical practice. Methods. Disproportionality analysis and Bayesian analysis were applied for data mining among the suspected adverse event reports of FG associated with SGLT2 inhibitors recorded in the FAERS database during the period from January 2004 to September 2019. Results. There were 542 FG cases identified in the FAERS database in patients receiving SGLT2 inhibitors. Among all SGLT2 inhibitor therapies, empagliflozin was associated with the highest number of FG reports (232 in total), while empagliflozin plus metformin had the strongest association with FG occurrence with the reporting odds ratio (ROR 54.79, 95% two-sided CI 31.56 to 95.12) and proportional reporting ratio (PRR 53.36, χ2 666.70). There were 391 patients who underwent initial or prolonged hospitalization (72.14%), and 26 patients died (4.81%). Three new FG cases caused by ertugliflozin were found in 2019. Conclusion. The analysis of SGLT2 inhibitor-associated FG reports in the FAERS database identified signals between the drug and adverse events of interest. It also provides comprehensive information on the characteristics of FG onset and prognosis. Clinicians should pay more attention to this rare but severe adverse event when prescribing SGLT2 inhibitors in clinical practice.http://dx.doi.org/10.1155/2020/3695101
spellingShingle Yang Hu
Ziyu Bai
Yan Tang
Rongji Liu
Bin Zhao
Jian Gong
Dan Mei
Fournier Gangrene Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Pharmacovigilance Study with Data from the U.S. FDA Adverse Event Reporting System
Journal of Diabetes Research
title Fournier Gangrene Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Pharmacovigilance Study with Data from the U.S. FDA Adverse Event Reporting System
title_full Fournier Gangrene Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Pharmacovigilance Study with Data from the U.S. FDA Adverse Event Reporting System
title_fullStr Fournier Gangrene Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Pharmacovigilance Study with Data from the U.S. FDA Adverse Event Reporting System
title_full_unstemmed Fournier Gangrene Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Pharmacovigilance Study with Data from the U.S. FDA Adverse Event Reporting System
title_short Fournier Gangrene Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Pharmacovigilance Study with Data from the U.S. FDA Adverse Event Reporting System
title_sort fournier gangrene associated with sodium glucose cotransporter 2 inhibitors a pharmacovigilance study with data from the u s fda adverse event reporting system
url http://dx.doi.org/10.1155/2020/3695101
work_keys_str_mv AT yanghu fourniergangreneassociatedwithsodiumglucosecotransporter2inhibitorsapharmacovigilancestudywithdatafromtheusfdaadverseeventreportingsystem
AT ziyubai fourniergangreneassociatedwithsodiumglucosecotransporter2inhibitorsapharmacovigilancestudywithdatafromtheusfdaadverseeventreportingsystem
AT yantang fourniergangreneassociatedwithsodiumglucosecotransporter2inhibitorsapharmacovigilancestudywithdatafromtheusfdaadverseeventreportingsystem
AT rongjiliu fourniergangreneassociatedwithsodiumglucosecotransporter2inhibitorsapharmacovigilancestudywithdatafromtheusfdaadverseeventreportingsystem
AT binzhao fourniergangreneassociatedwithsodiumglucosecotransporter2inhibitorsapharmacovigilancestudywithdatafromtheusfdaadverseeventreportingsystem
AT jiangong fourniergangreneassociatedwithsodiumglucosecotransporter2inhibitorsapharmacovigilancestudywithdatafromtheusfdaadverseeventreportingsystem
AT danmei fourniergangreneassociatedwithsodiumglucosecotransporter2inhibitorsapharmacovigilancestudywithdatafromtheusfdaadverseeventreportingsystem